Indeed, treatment of BCR-Abl B-ALL with a low dose of the tyrosine kinase inhibitor, Dasatinib, only mildly impacted control B-ALL cells, but B-ALL cell death was markedly increased in Glut1-deleted cells (Figure 5c). This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.